InsiderInsights.com Daily Ratings Report: February 3, 2025
InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process
KalVista Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The company's product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company has a portfolio of oral plasma kallikrein inhibitors and developed various drug candidates into clinical trials in order to create oral therapies for both HAE and DME. The company has initiated a clinical study of KVD900 as a therapy for acute HAE attacks. The company has also commenced a clinical trial of KVD001, its DME drug candidate.
PBF Energy is a holding company. Through its subsidiaries, the company is engaged as an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants and other petroleum products in the U.S. The company operates in two business segments: refining, which the company produces a variety of products at each of its refineries such as gasoline, ultra-low-sulfur diesel, heating oil, jet fuel, lubricants, petrochemicals and asphalt; and logistics, which through its PBF Logistics LP subsidiary, the company owns or leases, operates, develops and acquires crude oil and refined petroleum products terminals, pipelines, storage facilities and similar logistics assets.
Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat diseases with unmet medical needs. The company is developing a suite of clinical-stage drug candidates from its proprietary XmAb? technology platforms that are designed to treat cancer and autoimmune diseases. The company's protein engineering knowledge and the XmAb technologies are focused on the parts of the antibody that interacts with various segments of the immune system and controls antibody structure. This segment, referred to as the Fc domain, is constant and interchangeable among antibodies.
Insiderinsights' advanced insider analytics combine statistical track records with numerous behavioral metrics to rate the significance of a firm's insider trading history in real time.
Academic studies and the experience of professionals back the common sense conclusion that the Form 4 data filed daily at the SEC is a profitable data stream to mine for investment intelligence. But most investors use commodity insider feeds that are full of noise and time-consuming to analyze, or ratings services that employ last century's simplistic insider scoring methodology.
InsiderInsights compiles Daily, Weekly, and Monthly reports that list US equities with recent insider activity, along with proprietary Company Ratings clearly indicating the Significance Level of insider sentiment. Our monthly Special Screens further combine our Ratings with various fundamental and price action criteria, to highlight the best value, growth, momentum, and short ideas coming from the executive suite.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.